PHA Classroom: e-Learning. Anytime. Anyplace.

>> Back to Recordings

PH Treatments: What's on the Horizon

April 29, 2014

With the recent FDA approval of three new treatments in just a few months, the past year has brought exciting advances in PH research! Join Dr. Michael McGoon of the Mayo Clinic for a presentation on the current treatments available for PH, as well as new treatments in the pipeline.

Presenter Information

Michael McGoon, MD
Mayo Clinic
Michael McGoon, MD, is Professor of Medicine and Consultant in Cardiovascular Diseases at Mayo Clinic, Rochester, Minnesota. Dr. McGoon attended medical school and completed internship at Johns Hopkins before transferring to Mayo for residency and cardiology training. Dr. McGoon served as Director of the PH Center at Mayo since he initiated it in 1996 until 2007. He is board certified in Internal Medicine and Cardiology. For over 25 years, he has led multiple clinical trials of PH medications, starting with intravenous prostacyclin.  He recently served as chair of the Steering Committee of the REVEAL registry. Dr. McGoon has been a member of PHA’s Scientific Leadership Council since 1994, serving as Chair from 2002 to 2004 and as a Distinguished Advisor since 2004. He was Chair of the Board of Trustees of PHA (2006-2008), and currently chairs the Pulmonary Hypertension Care Centers Oversight Committee.

FacebookGoogle +TwitterLinkedInPinterestInstagramYouTubeBloggerFeedsPHAware Download our App

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
Webmaster@PHAssociation.org
    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2014 Pulmonary Hypertension Association. All Rights Reserved.

NORD

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.